4.10.27.5Vertical
Uro-Oncology Programs
Urologists specializing in prostate, bladder, and kidney cancer.
Market snapshot
These figures describe Urology (4.10.27), the segment that Uro-Oncology Programs sits within — not Uro-Oncology Programs on its own.
FragmentationConsolidatingEstimate
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so urology is not separately sized.
Business model & economics
Revenue model
Office, surgical, and rich ancillary reimbursement
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 20–30% with ancillaries
- Capex intensity
- Moderate
chronic and oncologic care recurs
Characteristics
- Hot specialty roll-up with rich ancillaries.
- In-office pathology, radiation, and surgery economics.
- Aging male population drives demand.
M&A deal context
Deal activityHigh
Who’s acquiring
- PE-backed urology platforms
- Specialty MSO consolidators
- Uro-oncology acquirers
What’s driving deals
- Roll-up for ancillary economics.
- Prostate-cancer and aging demand.
- Integrated uro-oncology models.
Find Uro-Oncology Programs acquisition targets
Search Acquisera’s index for companies classified under Uro-Oncology Programs (4.10.27.5) and build a targeted deal pipeline.
Search companies